Biochemie und Chemie
Refine
Year of publication
Document Type
- Article (1113)
- Doctoral Thesis (729)
- Book (46)
- Preprint (34)
- Contribution to a Periodical (14)
- Conference Proceeding (11)
- Report (11)
- Review (9)
- diplomthesis (3)
- Part of a Book (2)
Has Fulltext
- yes (1978)
Is part of the Bibliography
- no (1978)
Keywords
- crystal structure (37)
- Crystal Structure (25)
- Synthesis (15)
- ESR Spectra (14)
- RNA (14)
- NMR-Spektroskopie (12)
- hydrogen bonding (11)
- IR Spectra (10)
- NMR spectroscopy (10)
- RNS (9)
Institute
- Biochemie und Chemie (1978)
- Medizin (83)
- Exzellenzcluster Makromolekulare Komplexe (68)
- Biowissenschaften (64)
- Präsidium (64)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (63)
- Pharmazie (52)
- MPI für Biophysik (50)
- Sonderforschungsbereiche / Forschungskollegs (48)
- Georg-Speyer-Haus (22)
This paper contains further applications on symmetrical liquid mixtures of the molecular thermodynamic theory which has been developped in part I of this series. The essential feature of this theory is the superposition of "chemical" and “random” exchange equilibria between “complexes” formed by a given molecule and its z nearest neighbours, thus allowing a unified treatment of the thermodynamic phenomena in binary liquid mixtures using the equilibrium constant K of the ideal law of mass action and the energy w of pair interactions as parameters.
The temperature and pressure dependences of K and the evaluation of experimental excess enthalpy and excess volume data are treated. Formulas and examples for the calculation of K and w from isothermal and non-isothermal vapour-liquid equilibrium data are given. The conditions for azeotropy with minimum or maximum vapour pressure, resp., are derived. Melting curves for a symmetric eutectic system with superposed miscibility gap are discussed. Further models for partially miscible liquids with competing self-association and complex-formation are treated showing the phenomenon of two separated miscibility gaps.
The enthalpies of mixing at 25° of diethyl ether, di-n-propyl ether, di-n-butyl ether, di-isopropyl ether, propylene oxide, tetrahydrofuran, and tetrahydropyran with chloroform are determined by an isothermal titration method. As a result, the functions HM-f(N CHCl3) are obtained with a step width of 0.025 of the mole fraction and a relative accuracy of 1 per cent or better. Evaluation of the heat of mixing data by means of equilibrium models ("ideal associated mixture") shows that the systems of aliphatic ethers with chloroform behave rather precisely as one-step equilibria of the type A + B = AB (A = ether; B = chloroform). In the systems of cyclic ethers with chloroform, a second equilibrium step, AB + B = AB2 , must be considered, the importance of which decreases with increasing ring size of the ether. The equilibrium data calculated for the seven ether-diloroform systems are discussed.
As we have shown in a recent paper, the principle of competition between "statistical" and "chemical" mixing represents a molecular thermodynamic approach to all known types of phase separation. This principle is effective if the contributions of two independent spontaneous processes enter into the thermodynamic potential by which the resulting equilibrium state of the system is determined. This is equivalent with the statement that two different forms of entropy exist which are not interchangeable, and for which the law of increasing entropy independently must be valid. As "cooperativity" is introduced by this principle, critical phenomena may be described by simple equilibrium models in which only nearest-neighbour interactions are considered.
Starting from the molar Gibbs free energy GM of the most simple binary equilibrium model z = 1 with nearest-neighbour pairs, nonclassical critical-point exponents α = 0.33 of the molar heat capacity, β = 0.33 of the coexistence curve, γ = 1.33 of the isothermal compressibility, and δ = 4.33 of the critical isotherm, are derived, which are consistent with the well-known exponent in equalities. These non-classical critical-point exponents are independent of the chemical nature of the particles because they are obtained by applying thermodynamic arguments on the coupling constant τ, by which the contribution of "statistical mixing" to GM is weighted.
A generic drug product (World Health Organization (WHO) terminology: multisource product) is usually marketed and manufactured after the expiry date of the innovator’s patent. Generic drugs are less expensive than the innovator products because generic manufacturers do not have to amortize the investment costs of research, development, marketing, and promotion. Multisource products must contain the same active pharmaceutical ingredients (APIs) as the original formulation and have to be shown to be interchangeable with the original formulation. Multisource products have to be shown bioequivalent to the innovator counterpart with respect to pharmacokinetic and pharmacodynamic properties. Multisource products are therefore identical in dose, strength, route of administration, safety, efficacy, and intended use. Bioequivalence can be demonstrated by in vitro dissolution, pharmacokinetic, pharmacodynamic or clinical studies. Since 2000, the U.S. Food and Drug Administration (FDA) allows the approval of certain multisource products solely on the basis of in vitro studies, i.e. by waiving in vivo studies in humans (“Biowaiver”), based on the Biopharmaceutics Classification Scheme (BCS). The BCS characterizes APIs by their solubility and permeability in the gastrointestinal tract (GIT). The different BCS Classes I-IV (Class I: high solubility, high permeability; Class II: low solubility, high permeability; Class III: high solubility, low permeability and Class IV: low solubility, low permeability) result from all possible combinations of high and low solubility with high and low permeability. Since the adoption of the BCS by the FDA in 1995, the BCS criteria have been under continuous development. In 2006, the WHO has released the most recent bioequivalence guidance including relaxed criteria for bioequivalence studies based on modified BCS criteria. According to this guidance, APIs belonging to the BCS classes I – and under defined conditions - II and III – are eligible for a biowaiver-based approval. The principal objective of this work was to characterize the first-line anti tuberculosis APIs, isoniazid, pyrazinamide, ethambutol dihydrochloride and rifampicin, according to their physicochemical, biopharmaceutical, pharmacokinetic and pharmacological properties and to classify them according to the BCS. Ethambutol dihydrochloride and isoniazid were classified as borderline BCS class I/III APIs. Pyrazinamide was classified as a BCS class III and rifampicin as a BCS class II API. Based on the BCS classification and the additional criteria defined in the WHO bioequivalence guidance, the possibility of biowaiver-based approval for immediate release (immediate release) solid oral dosage forms containing the first-line antituberculosis drugs was evaluated. A biowaiver-based approval with defined constraints was recommended for immediate release solid oral dosage forms containing isoniazid (interaction with reducing sugars), pyrazinamide and ethambutol dihydrochloride (relative narrow therapeutic index). Rifampicin was classified as a BCS class II API, and it was concluded that rifampicin containing solid oral immediate release drug products as well as Scale-Up and Post-Approval Changes (SUPAC) changes should not be approved by a biowaiver on the following basis: (i) its solubility and dissolution are highly variable due to polymorphism and instability, (ii) concomitant intake of food and antacids reduces its absorption and bioavailability, (iii) no in vitro predictive dissolution test has been found which correlates to in vivo absorption and (iv) several publications reporting cases of non-bioequivalent and bioinequivalent rifampicin products have been located in the literature. Thus, it is recommended that bioequivalence of rifampicin containing solid oral immediate release drug products should be established by in vivo pharmacokinetic studies in humans. This risk-benefit benefit assessment of a biowaiver-based approval was presented as a poster at the American Association of Pharmaceutical Scientists (AAPS) 2005 and subsequently published as “Biowaiver Monographs” in the Journal of Pharmaceutical Sciences. Based on the assessment of the dissolution properties of the antituberculosis drugs for a biowaiver approval, quality control dissolution methodologies for the International Pharmacopoeia (Pharm. Int.) were developed, presented at the WHO expert meeting and adopted in the Pharm. Int. (http://www.who.int/medicines/publications/pharmprep/OMS_TRS_948.pdf). Additionally, preliminary biowaiver recommendations were also developed for four firstline antimalarial drugs listed on the WHO Essential Medicines List (EML): Quinine, as both the hydrochloride and sulphate, and proguanil hydrochloride were classified as borderline BCS class I/III APIs. Since quinine is a narrow therapeutic index drug and many cases of non-bioequivalence have been reported in the literature, a biowaiverbased approval was not recommended. For solid oral immediate release dosage forms containing proguanil a biowaiver-based approval was recommended under the condition that they dissolve very rapidly. Primaquine phosphate was classified as a BCS class I API. Therefore, a biowaiver-based approval was recommended for immediate release solid oral dosage forms containing primaquine phosphate. Mefloquine hydrochloride was classified as a basic, BCS class IV/II API, making it ineligible for the biowaiver. Additionally, reports of non-bioequivalence and a narrow therapeutic index were found in the scientific literature. Consequently, bioequivalence of solid oral immediate release dosage forms containing mefloquine hydrochloride should be established by in vivo pharmacokinetic studies. The results for quinine hydrochloride and sulphate, proguanil hydrochloride, primaquine diphosphate and mefloquine hydrochloride were presented as a poster at the Pharmaceutical Sciences World Congress (PSWC) 2007 and published as a WHO Collaborating Center Report in June 2006. The aim of this project was to collect, evaluate, generate and publish relevant information for a biowaiver-based approval of essential medicines in order to provide a summary to local regulatory authorities. This information complements the selected list of essential medicines by providing information about the biopharmaceutical properties and pharmaceutical quality of solid oral immediate release dosage forms containing these APIs. The aim of the biowaiver project, inspired by the WHO and brought in life by the International Pharmaceutical Federation (FIP), is to enable access to essential medicines in standardized quality at an affordable price. In this work, a significant contribution to this aim in the form of four biowaiver monographs for the antituberculosis drugs and several reports on the antimalarials has been achieved.
Determining the structure and mechanisms of all individual functional modules of cells at high molecular detail has often been seen as equal to understanding how cells work. Recent technical advances have led to a flush of high-resolution structures of various macromolecular machines, but despite this wealth of detailed information, our understanding of cellular function remains incomplete. Here, we discuss present-day limitations of structural biology and highlight novel technologies that may enable us to analyze molecular functions directly inside cells. We predict that the progression toward structural cell biology will involve a shift toward conceptualizing a 4D virtual reality of cells using digital twins. These will capture cellular segments in a highly enriched molecular detail, include dynamic changes, and facilitate simulations of molecular processes, leading to novel and experimentally testable predictions. Transferring biological questions into algorithms that learn from the existing wealth of data and explore novel solutions may ultimately unveil how cells work.
Bacterial sugar symporters in the Major Facilitator Superfamily (MFS) use the H+ (and in a few cases Na+) electrochemical gradients to achieve active transport of sugar into the cell. Because a number of structures of MFS sugar symporters have been solved recently, molecular insight into the transport mechanism is possible from detailed functional analysis. We present here a comparative electrophysiological study of the lactose permease (LacY), the fucose permease (FucP) and the xylose permease (XylE), which reveals common mechanistic principles and differences. In all three symporters energetically downhill electrogenic sugar/H+ symport is observed. Comparison of the pH dependence of symport at symmetrical pH exhibits broad bell-shaped pH profiles extending over 3 to 6 pH units and a decrease at extremely alkaline pH ≥ 9.4 and at acidic to neutral pH = 4.6–7.5. The pH dependence can be described by an acidic to neutral apparent pK (pKapp) and an alkaline pKapp. Experimental evidence suggests that the alkaline pKapp is due to H+ depletion at the protonation site, while the acidic pKapp is due to inhibition of deprotonation. Since previous studies suggest that a single carboxyl group in LacY (Glu325) may be the only side chain directly involved in H+ translocation and a carboxyl side chain with similar properties has been identified in FucP (Asp46) and XylE (Asp27), the present results imply that the pK of this residue is switched during H+/sugar symport in all three symporters.
Glioblastoma multiforme (GBM) is a deadly primary brain malignancy. Glioblastoma stem cells (GSC), which have the ability to self-renew and differentiate into tumor lineages, are believed to cause tumor recurrence due to their resistance to current therapies. A subset of GSCs is marked by cell surface expression of CD133, a glycosylated pentaspan transmembrane protein. The study of CD133-expressing GSCs has been limited by the relative paucity of genetic tools that specifically target them. Here, we present CD133-LV, a lentiviral vector presenting a single chain antibody against CD133 on its envelope, as a vehicle for the selective transduction of CD133-expressing GSCs. We show that CD133-LV selectively transduces CD133+ human GSCs in dose-dependent manner and that transduced cells maintain their stem-like properties. The transduction efficiency of CD133-LV is reduced by an antibody that recognizes the same epitope on CD133 as the viral envelope and by shRNA-mediated knockdown of CD133. Conversely, the rate of transduction by CD133-LV is augmented by overexpression of CD133 in primary human GBM cultures. CD133-LV selectively transduces CD133-expressing cells in intracranial human GBM xenografts in NOD.SCID mice, but spares normal mouse brain tissue, neurons derived from human embryonic stem cells and primary human astrocytes. Our findings indicate that CD133-LV represents a novel tool for the selective genetic manipulation of CD133-expressing GSCs, and can be used to answer important questions about how these cells contribute to tumor biology and therapy resistance.
In fungi, the mitochondrial respiratory chain complexes (complexes I–IV) are responsible for oxidative phosphorylation, as in higher eukaryotes. Cryo-EM was used to identify a 200 kDa membrane protein from Neurospora crassa in lipid nanodiscs as cytochrome c oxidase (complex IV) and its structure was determined at 5.5 Å resolution. The map closely resembles the cryo-EM structure of complex IV from Saccharomyces cerevisiae. Its ten subunits are conserved in S. cerevisiae and Bos taurus, but other transmembrane subunits are missing. The different structure of the Cox5a subunit is typical for fungal complex IV and may affect the interaction with complex III in a respiratory supercomplex. Additional density was found between the matrix domains of the Cox4 and Cox5a subunits that appears to be specific to N. crassa.
Mit kombinatorisch-chemischer Synthese und einem Gel-shift Test wurden niedermolekulare, peptidische RNA-Liganden gefunden. Als Target-Moleküle dienten ein 23mer RNA-Oligonukleotid (CETP-RNA) aus der Cholesterol Ester Transfer Protein mRNA und ein 27mer RNA-Oligonukleotid aus der HIV-1 Transactivation response region (TAR) RNA (delta-TAR-RNA). Zudem wurde erstmals die Methode des Phage Display angewendet, um RNA-Liganden zu finden. Die aus beiden Screeningmethoden erhaltenen Liganden wurden mit verschiedenen biophysikalischen Methoden, insbesonders der NMR-Spektroskopie auf ihre Bindungseigenschaften und mittels in vitro und in vivo-Tests auf ihre physiologische Aktivität hin untersucht. Ein 16mer Peptid der Antennapedia Homeodomäne internalisiert rasch in Zellen verschiedener Kulturen. Im Screening gefundene Peptidliganden wurde über flexible Spacer (2 beta-Ala-Einheiten) mit diesen 16mer synthetisiert. Es wurde gezeigt, daß diese Peptide so in die Zielzellen und besonders in deren Zellkern gelangen. Basische delta-TAR-RNA-Liganden zeigen diese Verhalten auch ohne Transportersequenz. Die Ergebnisse des Phage-Display-Screenings sind widersprüchlich, da die so gefundenen RNA-Liganden mit den genutzen biophysikalischen Methoden (NMR, CD, Gelelektrophorese) keine größere Affinität an die delta-TAR-RNA zeigen. Im physiologischen Test haben diese Liganden dennoch eine HIV-1 inhibitorische Aktivität gezeigt. In einer humanen Makrophagenkultur, der Wirtszelle von HIV, wurden mit den Peptiden Thr-Pro- Glu-Leu-Pro-Trp-His-NH2 und Phe-His-Ser-Val-Gln-Ala-Leu das HIV-1 Wachstum um 20- 30% inhibiert. Diese Ergebnisse widersprechen den strukturellen Bindungsinfornmationen und sind deshalb fraglich. Ein Monitoring während der Panning-Prozedur wurde nicht durchgeführt. Es wurde auch nicht überprüft, wieviel RNA wirklich immobilisiert wurde. Aufgrund der sehr geringen Substanzmengen was das nicht möglich. In einem deutlich größerem Maßstab, könnten in Zukunft strukturelle Informationen über die immobilisierte RNA gewonnen werden, z. B. mit HR-MAS-NMR-Techniken. Die im Gel-shift-Screening gefundenen delta-TAR-RNA-Liganden des Gel-shift-Screening zeigen keine HIV-1 inhibitorische Aktivität. Die gefundenen Bindungskonstanten sind allerdings um eine Größenordnung kleiner als die der natürliche Bindungsregion Tat10, welche eine HIV-1 inhibitorische Wirkung besitzt. Die im Gel-Shift-Screening gefundenen CETP-RNA/Peptid-Paare mit den stärksten Affinitäten wurden mittels NMR-Spektroskopie und CD- und Gel-shift-Experimenten charakterisiert. Die Bindungskonstanten lagen im niedrig mikromolaren Bereich. Wie in 1D Jump Return-Experimenten gezeigt wurde, verschoben sich die Signale verschiedener Liganden in Gegenwart der CETP-RNA unterschiedlich stark. Zudem konnte eine Verbreiterung der Signale der Liganden festgestellt werden. Das Peptid Lys-Tyr-Lys-Leu- Tyr-Lys-Cys-NH2 zeigte bei der CETP-RNA den stärksten Effekt mit Bindungsaffinitäten von Kd = 32±2 mikro-M (CD-Titration). In 2D NOESY Experimenten zeigt der Peptid-Ligand Kreuz-Signale zu den Iminoprotonen der CETP-RNA. Da die Sekundärstruktur der CETPRNA ein Hairpin ist, sollte das Peptid somit Kontakt zu der Doppelstrang-Region haben. Dieses Peptid zeigt zudem einen deutlichen Effekt auf das CD-Verhalten seiner CETP-RNA. Offenbar wird die Basenpaarung der Sekundärstruktur unter Peptideinfluß geschwächt. Im physiologischem Test am Tiermodell einer transgenen Maus zeigt dieser Ligand eine Erniedrigung des Cholesterolester Transfers. In Zukunft könnte das Peptid Lys-Tyr-Lys-Leu- Tyr-Lys-Cys-NH2 mit z. B. unnatürlichen Aminosäuren modifiziert werden, um eine bessere physiologische Stabilität zu erhalten und dadurch möglicherweise die physiologische Aktivität zu erhöhen. Auch eine Leitstrukturoptimierung kann durchgeführt werden.
Der CD95 Ligand (CD95L, FasL) ist ein Mitglied der Tumor-Nekrose-Faktor(TNF)- Superfamilie und ist in der Lage, Apoptose oder -unter bestimmten Bedingungen- Proliferation in CD95 Rezeptor-positiven Zellen auszulösen. Zusätzlich überträgt der CD95 Ligand aber auch als Rezeptor Signale in die ligandentragende Zelle, ein Phänomen, das auch bei anderen TNF-Familienmitgliedern beobachtet und als "reverse signalling" bezeichnet wird. Diese reverse Signalübertragung bewirkt in T-Zellen ein costimulatorisches Signal, welches zur vollständigen Aktivierung nach Antigen-Erkennung durch den T-Zellrezeptor (TZR) benötigt wird und über bisher unbekannte Adaptorproteine stattfindet, die vermutlich an den intrazellulären Anteil des CD95L binden. Die zytoplasmatische CD95L-Domäne ist auf Primärsequenzebene stark konserviert und besitzt eine prolinreiche Proteininteraktionsdomäne sowie eine Casein Kinase I Phosphorylierungsstelle, welche sich auch im intrazellulären Bereich des membrangebundenen TNFalpha findet und bei diesem Protein für die reverse Signalübertragung essentiell ist. Eine weitere Funktion des CD95L ist der Transport des Liganden zu einem speziellen Typ von Lysosomen in NK- und zytotoxischen T-Zellen. Hierfür ist die prolinreiche Region in der CD95L-intrazellulären Domäne wichtig. In diesen sekretorischen Lysosomen wird der CD95L gespeichert, bis er nach einem TZR-vermittelten Signal an die Zelloberfläche transportiert wird und dort mit dem CD95 Rezeptor der Ziel- Zellen interagieren kann. In der vorliegenden Arbeit wurde zur Aufklärung der oben beschriebenen Funktionen des CD95 Liganden ein Hefe-2-Hybrid Screen mit der intrazellulären CD95L-Domäne als Köder durchgeführt. Mit dieser Methode war es möglich, mehrere potentielle Interaktionspartner zu identifizieren. Eines dieser Proteine, FBP11, wurde schon zuvor als "human fas ligand associated factor" in der Datenbank veröffentlicht. Der HMG-Box-Transkriptionsfaktor Lef- 1, das Formin-bindende Protein FBP11, das thymozytenspezifische Protein TARPP und das Adaptorprotein PSTPIP ("proline serine threonin phosphatase interacting protein")/ CD2BP1 ("CD2 binding protein") interagierten in vitro in einem GST-Pulldown-Experiment mit der intrazellulären Domäne des CD95 Liganden. Mit Hilfe von Co- Immunpräzipitationsstudien und Co-Lokalisierungsexperimenten konnte die Interaktion von überexprimiertem CD95L und PSTPIP auch in vivo bestätigt werden. Des Weiteren wurde in dieser Arbeit gezeigt, dass diese Interaktion über eine nicht näher eingegrenzte Aminosäuresequenz in der prolinreichen Region des CD95L mit der SH3-Domäne des PSTPIP-Proteins realisiert wird. Die Phosphatase PTP-PEST bindet an einen Bereich der PSTPIP-Coiled-coil-Domäne, und es besteht die Möglichkeit, dass CD95L, PSTPIP und PTPPEST in der Zelle als ternärer Komplex vorliegen, in welchem der Phosphorylierungsstatus von PSTPIP und CD95L durch PTP-PEST reguliert wird. Wie die gleichzeitige Expression von PSTPIP die Oberflächenexpression von CD95L beeinflusst, war ein weiterer Untersuchungsgegenstand dieser Arbeit. Es konnte festgestellt werden, dass bei Überexpression von PSTPIP weniger CD95L auf der Oberfläche nachgewiesen wird. Interessanterweise wurde auch weniger Apoptose durch den CD95L ausgelöst, sobald PSTPIP überexprimiert wurde. Neben den Untersuchungen zur Interaktion von CD95L und PSTPIP (sowie PTP-PEST) wurden auch funktionelle Studien zur reversen Signalübertragung des CD95L durchgeführt. Sowohl in CD4- als auch in CD8-einzelpositiven frisch isolierten Maus-T-Zellen wurde ein co-stimulatorisches Signal nach suboptimaler TZR-Stimulation über CD95L beobachtet, was sich in verstärkter Proliferation und erhöhter Expression von Aktivierungsmarkern wie CD25 äußerte. Außerdem führt die Stimulation des CD95 Liganden zu einer transienten p42/p44-MAPK-Phosphorylierung, die durch Co-Expression von PSTPIP jedoch nicht beeinflusst wird. Die MAPK-Signalkaskade führt zur Zellproliferation und könnte daher eine wichtige Rolle in der CD95L-vermittelten Co- Stimulation spielen. Im Rahmen dieser Arbeit konnte auch zum ersten Mal gezeigt werden, dass die Lokalisation des CD95L in Lipid Rafts (Mikrodomänen der Zellmembran) wichtig für dessen apoptoseauslösendes Potential ist, da die Behandlung CD95L-positiver Zellen mit Substanzen, die Cholesterol entfernen und so Rafts zerstören, zur Inhibition der Apoptoseinduktion führt. Die Lokalisation sowohl des CD95 Rezeptors als auch des CD95 Liganden in unterschiedlichen Kompartimenten der Zellmembran könnte beide Moleküle voneinander abschirmen und so autokrine Apoptosemechanismen verhindern. Dadurch wird eine weitere Möglichkeit der Regulation der durch CD95L induzierten Apoptose realisiert.
The asymmetric unit of the title compound, C10H20I2Si2, contains two half-molecules. Both complete molecules are generated by crystallographic inversion centers located at the mid-points of the central C-C single bonds; the butadiene groups are planar, with a trans conformation about the central C-C bond. The molecules show short intramolecular H...I contacts of 2.89 and 2.92 Å. The crystal packing shows no short intermolecular contacts. Key indicators: single-crystal X-ray study; T = 155 K; mean σ(C–C) = 0.002 Å ; R factor = 0.021; wR factor = 0.059; data-to-parameter ratio = 43.6.
The title compound, C12H20N4O, undergoes a phase transition on cooling. The room-temperature structure is tetragonal (P43212, Z′ = 1), with the methoxybornyl group being extremely disordered. Below 213 K the structure is orthorhombic (P212121, Z′ = 2), with ordered molecules. The two independent molecules (A and B) have very similar conformations; significant differences only occur for the torsion angles about the Cbornyl—Ctetrazole bonds. The independent molecules are approximately related by the pseudo-symmetry relation: xB = −1/4 + yA, yB = 3/4 - xA and zB = 1/4 + zA. In the crystal, molecules are connected by N—H⋯N hydrogen bonds between the tetrazole groups, forming a pseudo-43 helix parallel to the c-axis direction. The crystal studied was a merohedral twin with a refined twin fraction value of 0.231 (2).
The absolute configuration of the title molecule, [Fe(C5H5)(C38H34NP2)]·CHCl3, is R,Rp. The molecular structure is similar to the structure of the solvent-free compound [Fukuzawa, Yamamoto & Kikuchi (2007). J. Org. Chem. 72, 1514-1517], but some torsion angles about the P-Cphenyl bonds differ by up to 25°. The P atoms and the N atom have a distorted trigonal-pyramidal geometry. The chloroform solvate group donates a C-H...[pi] bond to the central benzene ring and is also involved in six intermolecular C-H...Cl contacts with H...Cl distances between 2.96 and 3.13 Å. Key indicators: single-crystal X-ray study; T = 163 K; mean σ(C–C) = 0.003 Å; R factor = 0.039; wR factor = 0.088; data-to-parameter ratio = 24.2.
The title molecule, C34H28I4·4C6H6, has crystallographic 4 symmetry and crystallizes with four symmetry-related benzene solvent molecules. The phenyl group is eclipsed with one of the adamantane C—C bonds. The tetraphenyladamantane units and the benzene solvent molecules are connected by weak intermolecular phenyl–benzene C—H⋯π and benzene–benzene C—H⋯π interactions. In the crystal, molecules are linked along the c-axis direction via the iodophenyl groups by a combination of weak intermolecular I⋯I [3.944 (1) Å] and I⋯π(phenyl) [3.608 (6) and 3.692 (5) Å] interactions.
Dichlorido(3-phenylindenylidene)bis(triphenylphosphane)ruthenium(II) tetrahydrofuran disolvate
(2011)
The RuII atom in the title compound, [RuCl2(C15H10)(C18H15P)2]·2C4H8O, has a distorted square-pyramidal conformation. The P and Cl atoms are at the base of the pyramid and the Ru-Cindenylidene bond is in the axial position. The two Cl ligands and the two phosphane ligands are in trans positions. The Cl-Ru-Cl and P-Ru-P angles are 157.71 (2) and 166.83 (2)°, respectively. The two independent tetrahydrofuran (THF) solvent molecules are disordered. One THF molecule was refined using a split-atom model. The second THF molecule was accounted for by using program PLATON/SQUEEZE [Spek (2009). Acta Cryst. D65, 148-155]. The molecular conformation shows three intramolecular C-H...Cl contacts and two C-H...[pi] interactions while the crystal packing features an intermolecular C-H...Cl contact and two very weak intermolecular C-H...[pi] contacts.
The six-membered ring of the title compound, C11H16NO, has a distorted envelope conformation. The piperidine N atom deviates by 0.128 (1) Å from the plane through its three neighbouring atoms. In the crystal structure, molecules are connected by intermolecular Cethynyl-H...O contacts to form chains extending in the [10\overline{1}] direction. Key indicators: single-crystal X-ray study; T = 167 K; mean σ(C–C) = 0.001 Å ; R factor = 0.040; wR factor = 0.112; data-to-parameter ratio = 27.3.
The absolute configuration of the title compound, [Fe(C5H5)(C36H29OP2)], is Sp at the ferrocene group and S at the asymmetric C atom. Both P atoms have a trigonal-pyramidal conformation. There is a short intramolecular C-H...P contact with an H...P distance of 2.56 Å. The hydroxy group is involved in an intramolecular O-H...[pi]phenyl interaction. The crystal packing shows five very weak intermolecular C-H...[pi] contacts, with H...Cg distances between 3.26 and 3.39 Å (Cg is the centroid of a phenyl or cyclopentadienyl ring). Key indicators: single-crystal X-ray study; T = 162 K; mean σ(C–C) = 0.004 Å; R factor = 0.038; wR factor = 0.083; data-to-parameter ratio = 22.3.
Antibiotic resistance of pathogenic bacteria is a major worldwide problem. Bacteria can resist antibiotics by active efflux due to multidrug efflux pumps. The focus of this study has been the mycobacterial multidrug transporter TBsmr because it belongs to the small multidrug resistance (SMR) family whose members are a paradigm to study multidrug efflux due to their small size. SMR proteins are typically 11-12 kDa in size and have a four-transmembrane helix topology. They bind cationic, lipophilic antibiotics such as ethidium bromide (EtBr) and TPP+, and transport them across the membrane in exchange for protons. To understand the molecular mechanism of multidrug resistance, we have to gain information about the structure and function of these proteins. The research described in this thesis aimed to deduce details about the topology, transport cycle and key residues of TBsmr using biophysical techniques. Solid-state NMR (ssNMR) can provide detailed insight into structural organization and dynamical properties of these systems. However, a major bottleneck is the preparation of mg amounts of isotope labeled protein. In case of proteoliposomes, the problem is compounded by the presence of lipids which have to fit into the small active volume of the ssNMR rotor. In Chapter 3, an enhanced protein preparation is described which yields large amounts of TBsmr reconstituted in a native lipid environment suitable for further functional and structual studies. The achieved high protein-to-lipid ratios made a further characterization by ssNMR feasible. The transport activity and oligomeric state of the reconstituted protein in different types of lipid was studied as shown in Chapter 4. The exact oligomeric state of native SMR proteins is still uncertain but a number of biochemical and biophysical studies in detergent suggest that the minimal functional unit capable of binding substrate is a dimer. However, binding assays are not ideal since a protein may bind substrate without completing the transport cycle which can only be shown for reconstituted protein in transport assays.By combining functional data of a TPP+ transport assay with information about theoligomeric state of reconstituted TBsmr obtained by freeze-fracture electron microscopy, it could be shown that lipids affect the function and the oligomeric state of the protein, and that the TBsmr dimer is the minimal functional unit necessary for transport. The transport cycle must involve various conformational states of the protein needed for substrate binding, translocation and release. A fluorescent substrate will therefore experience a significant change of environment while being transported, which influences its fluorescence properties. Thus the substrate itself can report intermediate states that form during the transport cycle. In Chapter 5, the existence of such a substrate-transporter complex for the TBsmr and its substrate EtBr could be shown. The pH gradient needed for antiport has been generated by co-reconstituting TBsmr with bacteriorhodopsin. The measurements have shown the formation of a pH-dependant, transient substrate-protein complex between binding and release of EtBr. This state was further characterized by determining the Kd, by inhibiting EtBr transport through titration with non-fluorescent substrate and by fluorescence anisotropy measurements. The findings support a model with a single occluded intermediate state in which the substrate is highly immobile. Liquid-state NMR is a useful tool to monitor protein-ligand interactions by chemical shift mapping and thus identify and characterize important residues in the protein which are involved in substrate binding. In agreement with previous studies (Krueger-Koplin et al., 2004), the detergent LPPG was found to be highly suitable for liquid-state NMR studies of the membrane protein TBsmr and 42% of the residues could be assigned, as reported in Chapter 6. However, no specific interactions with EtBr were found. This observation was confirmed by LILBID mass spectrometry which showed that TBsmr was predominantly in the non-functional monomeric state. Functional protein was prepared in proteoliposomes which can be investigated by solidstate NMR (Chapter 7). Besides the essential E13, the aromatic residues W63, Y40, and Y60 have been shown to be directly involved in drug binding and transport. Different isotope labeling strategies were evaluated to improve the quality of the NMR spectra to identify and characterize these key residues. In a single tryptophan mutant of reconstituted TBsmr W30A, the binding of ethidium bromide could be detected by 13C solid-state NMR. The measurements have revealed two populations of the conserved W63 residue with distinct backbone structures in the presence of substrate. There is a controversy about the parallel or anti-parallel arrangement of the protomers in the EmrE dimer (Schuldiner, 2007) but this structural asymmetry is consistent with both a parallel and anti-parallel topology.
Autophagy, together with the ubiquitin-proteasome system, is the main quality control pathway responsible for maintaining cell homeostasis. There are several types of autophagy distinguished by cargo selectivity and means of induction. This thesis focuses on macroautophagy, hereafter autophagy, where a double-layered membrane is formed originating from the endoplasmatic reticulum (ER) engulfing cargo selectively or unselectively. Subsequently, a vesicle forms around the cargo, an autophagosome, and eventually fuses with the lysosome leading to degradation of the vesicle content and release of the cargo “building blocks”. Basal autophagy continuously occurs, unselectively engulfing a portion of the cytoplasm. However, autophagy can also be induced by stress such as starvation, protein aggregation, damaged organelles, intracellular pathogens etc. In this case, the cargo is selectively targeted, and the fate of the autophagosome is the same as in basal autophagy. In recent years, interest in identifying mechanisms of autophagy regulation has risen due to its importance in neurodegenerative diseases and cancer. Given the complexity of the process, its execution is tightly regulated from initiation, autophagosome formation, expansion, closure, and finally fusion with the lysosome. Each of the steps involves different protein complexes, whose timely activity is orchestrated by post-translational modifications. One of them is ubiquitination. Ubiquitin is a small, 76-amino acid protein conjugated in a 3-step reaction to other proteins, in a reversible manner, meaning undone by deubiquitinases. Originally described as a degradation signal targeting proteins to the proteasome, today it is known it has various additional non-proteolytic functions, such as regulating a protein’s activity, localization, or interaction partners. The role of ubiquitin in autophagy has already been shown. However, given the reversibility and fine-tuning of the ubiquitin signal, many expected regulators remain unidentified. This work aimed to identify novel deubiquitinating enzymes that regulate autophagy. We identified ubiquitin-specific protease 11 (USP11) as a novel, negative regulator of autophagy. Loss of USP11 leads to an increase in autophagic flux, whereas overexpression of USP11 attenuates it. Moreover, this observation was reproducible in model organism Caenorhabditis elegans, emphasizing the importance of USP11 in autophagy regulation. To identify the mechanism of USP11-dependent autophagy regulation, we performed a USP11 interactome screen after 4 hour Torin1 treatment and identified a plethora of autophagy-related proteins. Following the most prominent hits, we have investigated versatile ways in which USP11 regulates autophagy. USP11 interacts with the PI3KC3 complex, the role of which is phosphorylating lipids of the ER, thereby initiating the formation of the autophagosomal membrane. Phosphorylated lipids serve as a recruitment signal for downstream effector proteins necessary for the membrane expansion. The core components of the complex are VPS34, the lipid kinase, ATG14, the protein responsible for targeting the complex to the ER, VPS15, a pseudokinase with a scaffolding role, Beclin1, a regulatory subunit, and NRBF2, the dimer-inducing subunit. We have found USP11 interacts with the complex and, based on its activity, USP11 influences post-translational status of all the aforementioned subunits, except for ATG14. Moreover, we have found that loss of USP11 leads to an increase in NRBF2 levels, whereas it does not change the levels of the other proteins. Given that the dimerization of the complex leads to an increase in complex activity, we investigated if the complex is more tightly formed in the absence of USP11, and if it is more active. We have found both to be the case. Although the exact mechanism of USP11-dependent PI3KC3 complex regulation remains to be identified, we found that loss of USP11 stimulates the complex formation and activity, likely contributing to the general effect of USP11 on autophagy flux. Additionally, we found that USP11 modulates levels of mTOR, the most upstream kinase in autophagy initiation steps and general multifaceted metabolism regulator. Loss of USP11 led to downregulation of mTOR levels, suggesting USP11 may rescue mTOR from proteasome-mediated degradation. Furthermore, we found mTOR to be differentially modified depending on the activity of USP11. However, it remains to be shown if USP11-dependent mTOR regulation contributes to the observed autophagy phenotype. Taken together, USP11 is a novel, versatile, negative regulator of autophagy, and an important addition to our knowledge on the regulation of autophagy by the ubiquitin system.